Medtronic paces ahead
This article was originally published in The Gray Sheet
Executive Summary
Firm's Adapta, Versa and Sensia pacemakers offer "managed ventricular pacing" and "atrial capture management" to provide stimulation only as needed, the company said upon announcing the launch of the products. The technology has been shown to eliminate 99% of unnecessary pacing, reducing the risk of developing co-morbidities such as heart failure and atrial fibrillation, Medtronic says. The firm has been looking forward to this launch as a means of reasserting its hold on a vulnerable cardiac rhythm management market (1"The Gray Sheet" Feb. 27, 2006, p. 14)...
You may also be interested in...
Medtronic Readies New CRM Products To Protect Share Taken From Guidant
Medtronic is prepping three pacemakers for launch by May to compete against new products from competitor St. Jude and buttress against Guidant's potential comeback
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.